JP7513349B2 - ＧｌｙＴ１阻害剤の固体形態 - Google Patents

ＧｌｙＴ１阻害剤の固体形態 Download PDF

Info

Publication number
JP7513349B2
JP7513349B2 JP2021563717A JP2021563717A JP7513349B2 JP 7513349 B2 JP7513349 B2 JP 7513349B2 JP 2021563717 A JP2021563717 A JP 2021563717A JP 2021563717 A JP2021563717 A JP 2021563717A JP 7513349 B2 JP7513349 B2 JP 7513349B2
Authority
JP
Japan
Prior art keywords
compound
ppm
solid
crystalline polymorph
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021563717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530630A (ja
Inventor
ジョー ジュ ガオ
ペーター ジーガー
ビン－ショウ ヤン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2022530630A publication Critical patent/JP2022530630A/ja
Priority to JP2024074707A priority Critical patent/JP7714727B2/ja
Application granted granted Critical
Publication of JP7513349B2 publication Critical patent/JP7513349B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021563717A 2019-05-01 2020-04-30 ＧｌｙＴ１阻害剤の固体形態 Active JP7513349B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024074707A JP7714727B2 (ja) 2019-05-01 2024-05-02 ＧｌｙＴ１阻害剤の固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962841401P 2019-05-01 2019-05-01
US62/841,401 2019-05-01
PCT/US2020/030580 WO2020223419A1 (en) 2019-05-01 2020-04-30 Solid forms of a glyt1 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024074707A Division JP7714727B2 (ja) 2019-05-01 2024-05-02 ＧｌｙＴ１阻害剤の固体形態

Publications (2)

Publication Number Publication Date
JP2022530630A JP2022530630A (ja) 2022-06-30
JP7513349B2 true JP7513349B2 (ja) 2024-07-09

Family

ID=70740812

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021563717A Active JP7513349B2 (ja) 2019-05-01 2020-04-30 ＧｌｙＴ１阻害剤の固体形態
JP2024074707A Active JP7714727B2 (ja) 2019-05-01 2024-05-02 ＧｌｙＴ１阻害剤の固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024074707A Active JP7714727B2 (ja) 2019-05-01 2024-05-02 ＧｌｙＴ１阻害剤の固体形態

Country Status (25)

Country Link
US (2) US11447474B2 (https=)
EP (1) EP3962911A1 (https=)
JP (2) JP7513349B2 (https=)
KR (1) KR20220004174A (https=)
CN (1) CN113784966B (https=)
AR (1) AR118839A1 (https=)
AU (1) AU2020266566B2 (https=)
BR (1) BR112021020883A2 (https=)
CA (1) CA3138288A1 (https=)
CL (2) CL2021002837A1 (https=)
CO (1) CO2021014260A2 (https=)
CR (1) CR20210545A (https=)
DO (1) DOP2021000224A (https=)
EA (1) EA202192925A1 (https=)
EC (1) ECSP21082195A (https=)
IL (1) IL287630A (https=)
JO (1) JOP20210295A1 (https=)
MA (1) MA55801A (https=)
MX (1) MX2021013341A (https=)
PE (1) PE20212263A1 (https=)
PH (1) PH12021552741A1 (https=)
SG (1) SG11202111972YA (https=)
TW (1) TW202106680A (https=)
UA (1) UA129159C2 (https=)
WO (1) WO2020223419A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024100792A (ja) * 2019-05-01 2024-07-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＧｌｙＴ１阻害剤の固体形態

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
US11813257B2 (en) 2020-01-09 2023-11-14 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
MX2023001818A (es) * 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking
WO2025140479A1 (zh) * 2023-12-29 2025-07-03 苏州科睿思制药有限公司 Iclepertin的晶型及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524414A (ja) 2011-08-03 2014-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フェニル−３−アザ−ビシクロ［３．１．０］ヘキサ−３−イル−メタノン及び薬物としてのこれらの使用
WO2018199235A1 (ja) 2017-04-27 2018-11-01 武田薬品工業株式会社 複素環化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
RS20060190A (sr) * 2003-10-14 2008-08-07 Pfizer Products Inc., Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
CA2745690A1 (en) * 2008-12-04 2010-06-10 Evgeny Zlotinikov Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative
EP2381941A4 (en) * 2008-12-29 2012-08-01 Univ Vanderbilt 3.1.0 BICYCLIC GLYTI INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EA202192925A1 (ru) * 2019-05-01 2022-03-23 Бёрингер Ингельхайм Интернациональ Гмбх Твердые формы ингибитора glyt1
MX2023001818A (es) * 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) * 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524414A (ja) 2011-08-03 2014-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フェニル−３−アザ−ビシクロ［３．１．０］ヘキサ−３−イル−メタノン及び薬物としてのこれらの使用
WO2018199235A1 (ja) 2017-04-27 2018-11-01 武田薬品工業株式会社 複素環化合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
実験化学講座（続）２ 分離と精製，日本，丸善株式会社，1967年01月25日，p.159-178,186-187
山野光久，医薬品のプロセス研究における結晶多形現象への取り組み，有機合成化学協会誌，2007年09月01日，Vol.65, No.9，p.907(69)-913(75)
新・薬剤学総論（改訂第３版），株式会社南江堂，1987年04月10日，p.111
新製剤学，株式会社南山堂，1984年04月25日，p.102-103,232-233
芦澤一英 他，医薬品の多形現象と晶析の科学，日本，丸善プラネット株式会社，2002年09月20日，p.3-16,273-278
高田則幸，創薬段階における原薬Formスクリーニングと選択，PHARM STAGE，Vol.6, No.10，2007年01月15日，p.20-25

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024100792A (ja) * 2019-05-01 2024-07-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＧｌｙＴ１阻害剤の固体形態
JP7714727B2 (ja) 2019-05-01 2025-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＧｌｙＴ１阻害剤の固体形態

Also Published As

Publication number Publication date
CN113784966B (zh) 2024-07-19
JOP20210295A1 (ar) 2023-01-30
JP2024100792A (ja) 2024-07-26
DOP2021000224A (https=) 2021-12-15
TW202106680A (zh) 2021-02-16
NZ781254A (en) 2025-03-28
CR20210545A (es) 2021-12-23
JP7714727B2 (ja) 2025-07-29
JP2022530630A (ja) 2022-06-30
CL2021002837A1 (es) 2022-07-29
PH12021552741A1 (en) 2022-07-11
PE20212263A1 (es) 2021-11-29
CA3138288A1 (en) 2020-11-05
EA202192925A1 (ru) 2022-03-23
EP3962911A1 (en) 2022-03-09
ECSP21082195A (es) 2021-12-30
WO2020223419A1 (en) 2020-11-05
AU2020266566B2 (en) 2025-11-06
MX2021013341A (es) 2021-11-17
US11447474B2 (en) 2022-09-20
MA55801A (fr) 2022-03-09
US20220332710A1 (en) 2022-10-20
AR118839A1 (es) 2021-11-03
CL2024000829A1 (es) 2024-09-27
KR20220004174A (ko) 2022-01-11
IL287630A (en) 2021-12-01
US20200347041A1 (en) 2020-11-05
SG11202111972YA (en) 2021-11-29
AU2020266566A1 (en) 2021-11-11
CO2021014260A2 (es) 2021-10-29
UA129159C2 (uk) 2025-01-29
BR112021020883A2 (pt) 2022-04-19
CN113784966A (zh) 2021-12-10

Similar Documents

Publication Publication Date Title
JP7714727B2 (ja) ＧｌｙＴ１阻害剤の固体形態
ME00466B (me) Tartaratne soli 5,8,14-triazatetraciklo( 10.3.1.02,11.04,9)-heksadeka-2 (11),3,5,7,9-pentaena
CN115989019A (zh) β肾上腺素能激动剂的形式和组合物
CN103974949A (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
JP2018527363A (ja) リナグリプチン結晶形及びこの製造方法
EP2297152A1 (en) Anhydrous crystal form of orvepitant maleate
JP2024056724A (ja) ムスカリン性アセチルコリン受容体アゴニストの結晶性多形
JP6483105B2 (ja) ピペラジン誘導体および医薬としてのその使用
WO2018170214A1 (en) Analogs of deutetrabenazine, their preparation and use
EA045384B1 (ru) Твердые формы ингибитора glyt1
US20060030602A1 (en) (S)-amlodipine malate
JP2023520164A (ja) ５－ｈｔ３受容体モジュレーター、結晶形態、それらの製造方法及び使用
KR102399374B1 (ko) 알츠하이머병의 치료를 위한 ｎ-[2-(6-플루오로-1ｈ-인돌-3-일)에틸]-3-(2,2,3,3-테트라플루오로프로폭시)벤질아민 히드로클로라이드의 신규한 다형체 형태
CN106749196B (zh) 一种5-羟色胺受体激动剂
JP2025503063A (ja) 硫黄含有イソインドリン系誘導体の結晶
WO2017058689A1 (en) Crystal forms of a m1 receptor positive allosteric modulator
RS66214B1 (sr) Kokristali (1r,3s)-3-(5-cijano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentan karboksilne kiseline
EA051825B1 (ru) Кристаллические полиморфы агониста мускаринового рецептора ацетилхолина
JP2011522016A (ja) ４−ブロモフェニル１，４−ジアザビシクロ［３．２．２］ノナン−４−カルボキシラートのフマル酸塩、この結晶形態、調製、および治療的使用
JP2013507420A (ja) パルドプルノックスの多形
OA18216A (en) Novel polymorphic form of N-[2-(6-fluoro-LHindol-3-YI)ethyl]-3-(2,2,3,3-tetrafluoropropoxy) benzylamine hydrochloride for the treatment of Alzheimer's.
CN101175751A (zh) 具有哌啶环的吲哚衍生物的晶体和其制备方法
HK1236528B (en) Novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer's
HK1236528A1 (en) Novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer's

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240624

R150 Certificate of patent or registration of utility model

Ref document number: 7513349

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150